-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-2074 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-2074 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-2074 in Solid Tumor Drug Details: ASP-2074 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab Vedotin in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Diffuse Large B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Celiprolol in Ehlers-Danlos Syndrome Vascular Type (Type IV)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Celiprolol in Ehlers-Danlos Syndrome Vascular Type (Type IV) Drug Details: Celiprolol (ACER-002) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Celiprolol in Ehlers-Danlos Syndrome Vascular Type (Type IV)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Celiprolol in Ehlers-Danlos Syndrome Vascular Type (Type IV)Drug Details:Celiprolol (ACER-002) is under development for the treatment...
-
Company Profile
Acer Therapeutics Inc – Company Profile
Acer Therapeutics Inc (Acer) is a pharmaceutical company that develops and commercializes drugs for serious, rare and life-threatening diseases. The company’s pipeline products include EDSIVO, ACER-801 and OLPRUVA. Its EDSIVO and ACER-801 candidates treat vascular ehlers-danlos syndrome (vEDS), vasomotor symptoms (VMS), post-traumatic stress disorder (PTSD) and prostate cancer. The company's OLPRUVA (sodium phenylbutyrate) for oral suspension, candidate treats urea cycle disorders and (UCDs) and maple syrup urine disease (MSUD). Acer is headquartered in Newton, Massachusetts, the US.
Add to Basket -
Product Insights
Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Zika Virus Infections Pipeline Drugs Market Report Overview Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The Zika Virus Infections pipeline drugs market research report provides comprehensive information on the Zika...
-
Product Insights
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dengue Fever Pipeline Drugs Market Report Overview Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style. The dengue fever pipeline...
-
Product Insights
Net Present Value Model: Sodium phenylbutyrate IR
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sodium phenylbutyrate IR Drug Details Sodium...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – sodium phenylbutyrate IR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry sodium phenylbutyrate IR Drug Details Sodium phenylbutyrate immediated release (ACER-001) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – osanetant
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry osanetant Drug Details Osanetant (ACER-801) is under development for the treatment of induced vasomotor...